Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

ORASURE TECHNOLOGIES

OraSure Technologies develops, manufactures and distributes oral fluid diagnostic and collection devices and other te... read more Featured Products: More products

Download Mobile App




New Rapid Ebola Antigen Test Detects Infection at Point of Care

By LabMedica International staff writers
Posted on 23 Jul 2026

A serious Ebola epidemic centered in the Democratic Republic of the Congo has caused hundreds of deaths and triggered a global public health emergency, with cases also reported in Uganda. More...

Rapid diagnosis is critical, including confirmation in recently deceased individuals, but response efforts are complicated by the Bundibugyo virus, which has no approved vaccine or targeted treatment. A newly authorized rapid antigen test now supports time-critical detection at or near the point of care, delivering results in 30 minutes.

OraSure Technologies' OraQuick Ebola 2.0 Rapid Antigen Test has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for use with whole blood from living patients and cadaveric oral fluid from individuals suspected of having Ebola disease at the time of death. The second‑generation assay detects all four Ebola viruses known to cause human disease: Bundibugyo, Zaire, Sudan, and Taï Forest. The authorization encompasses use in symptomatic individuals with known risk factors and in the deceased to guide safe handling and burial.

The test is a single‑use, qualitative immunoassay that detects antigens from viruses within the Orthoebolavirus genus, though it does not differentiate between specific Ebola viruses. Results are read directly on the device at 30 minutes without instruments, batteries, smartphones, or laboratory analysis. The format is designed to support rapid triage and infection control in resource‑constrained or decentralized settings.

OraQuick Ebola 2.0 follows the company’s first‑generation OraQuick Ebola Rapid Antigen Test, which received De Novo marketing authorization in 2019 as the first and only rapid antigen test with full authorization for Ebola virus detection. The new version incorporates increased sensitivity, a new assay chemistry, and a more automated manufacturing process. 

The ongoing Ebola outbreak, concentrated in the Democratic Republic of the Congo and spreading into neighboring Uganda, has caused hundreds of deaths and led the World Health Organization to declare a global public health emergency. In response, the company is increasing production of the OraQuick Ebola 2.0 Rapid Antigen Test to address potential demand and broaden access to a reliable, proven diagnostic tool.

“We are proud to advance a second-generation Ebola test at a time when the world is confronting a serious and evolving outbreak in Central Africa. This outbreak is particularly challenging due to the Bundibugyo virus, which has no approved vaccine or targeted treatment, reinforcing the critical need for rapid, accurate diagnostics that can detect this virus and support timely containment efforts,” said Carrie Eglinton Manner, President and CEO of OraSure.



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.